Vivus Sells EvaMist Rights To KV For $150 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Vivus CEO tells “The Pink Sheet” DAILY that sale of estrogen product will allow firm to focus on obesity candidate Qnexa.